CANNABIS BIOSCI INTL HLDG (CBIH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Apr 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CBIH SEC filings page.
CANNABIS BIOSCI INTL HLDG (CBIH) reported $303K in revenue for fiscal year 2025, up 21.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is offsetting operating cash use while expanding liabilities faster than the asset base.
In FY2024, financing inflows of$471K nearly matched the operating cash outflow of$479K , indicating that operations were not self-funded. By FY2025, liabilities reached$1.2M against only$32K of assets, making the funding pattern a structural balance-sheet issue rather than a one-year cash gap.
Gross margin climbed from
By FY2025, liabilities of
Financial Health Signals
CANNABIS BIOSCI INTL HLDG does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CANNABIS BIOSCI INTL HLDG scores -326.39, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.2M) relative to total liabilities ($1.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CANNABIS BIOSCI INTL HLDG passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
CANNABIS BIOSCI INTL HLDG reported a net loss of $549K while operations used $330K of cash. With neither figure positive, the ratio between the two carries no quality signal.
CANNABIS BIOSCI INTL HLDG reported an operating loss of $421K against $136K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CANNABIS BIOSCI INTL HLDG generated $11K in revenue in Q3 2026. This represents a decrease of 25.0% from the same quarter a year earlier. Against the prior quarter it is down 79.0%.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
CANNABIS BIOSCI INTL HLDG held $90 in cash against $250K in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
CANNABIS BIOSCI INTL HLDG's gross margin was 72.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 102.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.5 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
None of these metrics is reported for Q3 2026.
CBIH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11K-25.0% | $53K-28.3% | $24K-86.5% | $35K-53.9% | $15K-59.0% | $74K+16.5% | $179K+145.7% | $76K |
| Cost of Revenue | $3K-84.3% | $11K+34.6% | $8K-2.6% | $5K-54.0% | $19K+64.2% | $8K-48.3% | $8K-5.2% | $10K |
| Gross Profit | $8K+282.8% | $43K-35.6% | $16K-90.6% | $30K-53.9% | -$4K-118.1% | $66K+36.6% | $171K+166.4% | $66K |
| SG&A Expenses | $27K-46.5% | $31K-22.8% | $23K-62.0% | -$50K-218.4% | $50K+98.4% | $40K+377.3% | $61K+27.5% | $42K |
| Operating Income | N/A | -$96K-60.8% | -$75K+23.4% | N/A | N/A | -$60K+36.9% | -$98K+44.8% | -$55K |
| Interest Expense | $11K-52.0% | $18K+105.3% | $17K+642.5% | $103K+46.7% | $22K-54.3% | $9K-70.9% | $2K-53.3% | $70K |
| Net Income | N/A | -$117K-47.1% | -$83K-8.3% | N/A | N/A | -$80K+36.1% | -$76K+58.0% | -$136K |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Diluted Shares (Avg) | 11.63B+8.4% | 11.63B+10.8% | 11.63B+11.2% | N/A | 10.73B+3.4% | 10.50B+1.6% | 10.46B+1.2% | N/A |
Not reported in any period shown, so not listed: R&D Expenses, EBITDA, Income Tax.
CBIH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2K-89.6% | $22K | $19K-59.1% | $32K-44.2% | $15K-84.2% | N/A | $46K | $57K+31.8% |
| Current Assets | $2K-59.2% | $22K | $19K+1.1% | $29K+35.3% | $4K-79.5% | N/A | $19K | $21K+10.4% |
| Cash & Equivalents | $90-83.6% | $132-86.8% | $223-77.0% | $13K+1615.5% | $548-31.0% | $1K+197.3% | $969-79.6% | $755-91.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $1K-52.0% | $22K | $9K-47.8% | $6K-68.3% | $3K-84.5% | N/A | $17K | $20K+102.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.5M+18.4% | $1.4M | $1.3M+14.8% | $1.2M+5.2% | $1.2M+15.9% | N/A | $1.1M | $1.1M+78.9% |
| Current Liabilities | $1.2M+25.7% | $1.1M | $1.0M+19.2% | $946K+7.3% | $970K+21.1% | N/A | $852K | $882K+128.7% |
| Non-Current Liabilities | $250K-7.7% | $250K | $250K0.0% | $250K-1.9% | $270K+0.5% | N/A | $250K | $254K+1.9% |
| Long-Term Debt | $250K0.0% | $250K | $250K0.0% | $250K+0.1% | $250K0.0% | N/A | $250K | $249K-0.1% |
| Total Equity | -$1.5M-19.7% | -$1.4M-20.1% | -$1.2M-18.1% | -$1.2M-7.8% | -$1.2M-25.6% | -$1.1M-34.8% | -$1.1M-47.1% | -$1.1M-82.4% |
| Retained Earnings | -$6.2M-9.1% | -$6.1M | -$6.0M-10.3% | -$5.9M-10.3% | -$5.7M-9.1% | N/A | -$5.4M | -$5.3M-13.9% |
Not reported in any period shown, so not listed: Inventory, Goodwill.
CBIH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
CBIH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.8%+102.7pp | 80.3%-9.2pp | 66.3%-29.0pp | 87.0%0.0pp | -29.9%-97.5pp | 89.5%+13.2pp | 95.3%+7.4pp | 87.0% |
| Operating Margin | N/A | -180.0% | -309.0% | N/A | N/A | -80.3% | -54.6% | -72.3% |
| Net Margin | N/A | -219.6% | -341.5% | N/A | N/A | -107.1% | -42.7% | -179.2% |
| Return on Assets | N/A | -528.5% | -436.3%-271.4pp | N/A | N/A | N/A | -164.9% | -237.8% |
| Current Ratio | 0.000.0x | 0.02 | 0.020.0x | 0.030.0x | 0.000.0x | N/A | 0.02 | 0.020.0x |
| Asset Turnover | 7.26+6.3x | 2.41 | 1.28-2.6x | 1.10-0.2x | 1.00+0.6x | N/A | 3.87 | 1.33 |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$1.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CANNABIS BIOSCI INTL HLDG CBIH | FY2025 | $303K | -$549K | N/A | $1.2M | — |
| MARIJUANA INC MAJI | FY2020 | $0 | N/A | N/A | $275K | — |
Where CANNABIS BIOSCI INTL HLDG Ranks
Frequently Asked Questions
What is CANNABIS BIOSCI INTL HLDG's annual revenue?
CANNABIS BIOSCI INTL HLDG (CBIH) reported $303K in total revenue for fiscal year 2025. This represents a 21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CANNABIS BIOSCI INTL HLDG's revenue growing?
CANNABIS BIOSCI INTL HLDG (CBIH) revenue grew by 21.8% year-over-year, from $249K to $303K in fiscal year 2025.
Is CANNABIS BIOSCI INTL HLDG profitable?
No, CANNABIS BIOSCI INTL HLDG (CBIH) reported a net income of -$549K in fiscal year 2025.
How much debt does CANNABIS BIOSCI INTL HLDG have?
As of fiscal year 2025, CANNABIS BIOSCI INTL HLDG (CBIH) had $13K in cash and equivalents against $250K in long-term debt.
What is CANNABIS BIOSCI INTL HLDG's gross margin?
CANNABIS BIOSCI INTL HLDG (CBIH) had a gross margin of 86.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is CANNABIS BIOSCI INTL HLDG's operating cash flow?
CANNABIS BIOSCI INTL HLDG (CBIH) recorded an outflow of $330K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CANNABIS BIOSCI INTL HLDG's total assets?
CANNABIS BIOSCI INTL HLDG (CBIH) had $32K in total assets as of fiscal year 2025, including both current and long-term assets.
What is CANNABIS BIOSCI INTL HLDG's current ratio?
CANNABIS BIOSCI INTL HLDG (CBIH) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is CANNABIS BIOSCI INTL HLDG's return on assets (ROA)?
CANNABIS BIOSCI INTL HLDG (CBIH) had a return on assets of -1721.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CANNABIS BIOSCI INTL HLDG's P/E ratio?
CANNABIS BIOSCI INTL HLDG (CBIH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.2M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CANNABIS BIOSCI INTL HLDG's price-to-sales ratio?
CANNABIS BIOSCI INTL HLDG (CBIH) trades at 9.4x sales, its market capitalization divided by revenue of $124K revenue, trailing 12 months to February 28, 2026. The market capitalization is $1.2M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CANNABIS BIOSCI INTL HLDG's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CANNABIS BIOSCI INTL HLDG (CBIH) held $13K in cash, cash equivalents and investments, and reported an operating cash outflow of $330K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is CANNABIS BIOSCI INTL HLDG's debt-to-equity ratio negative or not reported?
CANNABIS BIOSCI INTL HLDG (CBIH) has negative shareholder equity of -$1.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is CANNABIS BIOSCI INTL HLDG's Altman Z-Score?
CANNABIS BIOSCI INTL HLDG (CBIH) has an Altman Z-Score of -326.39, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CANNABIS BIOSCI INTL HLDG's Piotroski F-Score?
CANNABIS BIOSCI INTL HLDG (CBIH) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CANNABIS BIOSCI INTL HLDG's earnings high quality?
CANNABIS BIOSCI INTL HLDG (CBIH) reported a net loss of $549K while operations used $330K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CANNABIS BIOSCI INTL HLDG cover its interest payments?
CANNABIS BIOSCI INTL HLDG (CBIH) reported an operating loss of $421K against $136K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.